2-ethoxycarbonylaminothiazolo/4,5-b/pyrazine | 112342-69-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-ethoxycarbonylaminothiazolo/4,5-b/pyrazine
• 英文别名: ethyl thiazolo[4,5-b]pyrazin-2-ylcarbamate；ethyl N-([1,3]thiazolo[4,5-b]pyrazin-2-yl)carbamate
• CAS: 112342-69-5
• 化学式: C₈H₈N₄O₂S
• 分子量: 224.243
• InChiKey: NGLASTUGACDUEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-ethoxycarbonylaminothiazolo/4,5-b/pyrazine 在 sodium hydroxide 、 溴 、 sodium acetate 、 溶剂黄146 作用下， 反应 7.0h， 生成 2-氨基-6-溴噻唑并[4,5-B]吡嗪
  参考文献：
  名称：

  Koren, Bozidar; Stanovnik, Branko; Tisler, Miha, Heterocycles, 1987, vol. 26, # 3, p. 689 - 697

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl N-(pyrazin-2-ylcarbamothioyl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 以84%的产率得到2-ethoxycarbonylaminothiazolo/4,5-b/pyrazine
  参考文献：
  名称：

  HMOX1 inducers

  摘要：

  本发明涉及结构（I）的化合物作为血红素氧合酶1（HMOX 1）诱导剂。本发明还涉及一种控制哺乳动物体内血红素氧合酶1的活性或数量，或活性和数量的方法。这里提供了变量的定义。

  公开号：

  US10766888B1

文献信息

• HMOX1 inducers
  申请人：Mitobridge Inc.

  公开号：US10766888B1

  公开（公告）日：2020-09-08

  The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

  本发明涉及结构（I）的化合物作为血红素氧合酶1（HMOX 1）诱导剂。本发明还涉及一种控制哺乳动物体内血红素氧合酶1的活性或数量，或活性和数量的方法。这里提供了变量的定义。
• Oxime Derivative and Preparations Thereof
  申请人：Sugawara Kazutoshi

  公开号：US20080132479A1

  公开（公告）日：2008-06-05

  The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]: wherein Ring A is aryl or heteroaryl; Q is cycloalkyl, heterocycle, alkyl or alkenyl; Ring T is heteroaryl or heterocycle; R 1 and R 2 are independently hydrogen atom, halogen atom, cycloalkylsulfonyl or the like; R 3 and R 4 are independently hydrogen atom, hydroxy, oxo, halogen atom or the like; R 5 is hydrogen atom, halogen atom, cyano, nitro, tetrazolyl or the like; or a pharmaceutically acceptable salt thereof.

  本发明的问题是提供一种有用的化合物作为葡萄糖激酶活化剂，其为式[I]的肟衍生物：其中，环A是芳基或杂芳基；Q是环烷基，杂环，烷基或烯基；环T是杂芳基或杂环；R1和R2分别是氢原子，卤素原子，环烷基磺酰基或类似物；R3和R4分别是氢原子，羟基，氧代，卤素原子或类似物；R5是氢原子，卤素原子，氰基，硝基，四唑基或类似物；或其药学上可接受的盐。
• OXIME DERIVATIVE AND PREPARATIONS THEREOF
  申请人：Sugawara Kazutoshi

  公开号：US20090291936A1

  公开（公告）日：2009-11-26

  The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]: wherein Ring A is aryl or heteroaryl; Q is cycloalkyl, heterocycle, alkyl or alkenyl; Ring T is heteroaryl or heterocycle; R 1 and R 2 are independently hydrogen atom, halogen atom, cycloalkylsulfonyl or the like; R 3 and R 4 are independently hydrogen atom, hydroxy, oxo, halogen atom or the like; R 5 is hydrogen atom, halogen atom, cyano, nitro, tetrazolyl or the like; or a pharmaceutically acceptable salt thereof.

  本发明的问题是提供一种有用的化合物作为葡萄糖激酶活化剂，该化合物是公式[I]的肟衍生物： 其中，环A是芳基或杂环芳基；Q是环烷基、杂环、烷基或烯基；环T是杂环芳基或杂环；R1和R2分别是氢原子、卤素原子、环烷基磺酰基或类似物；R3和R4分别是氢原子、羟基、氧代、卤素原子或类似物；R5是氢原子、卤素原子、氰基、硝基、四唑基或类似物；或其药学上可接受的盐。
• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Array BioPharma Inc.

  公开号：US20130065901A1

  公开（公告）日：2013-03-14

  Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了一些化合物，它们在治疗和/或预防由葡萄糖激酶活性不足引起的疾病中非常有用，例如糖尿病。此外，还提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶来治疗的疾病和障碍的方法。
• 2-aminopyridine analogs as glucokinase activators
  申请人：Array Biopharma, Inc.

  公开号：EP2543667A1

  公开（公告）日：2013-01-09

  Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  所提供的式 I 化合物可用于治疗和/或预防由葡萄糖激酶活性水平不足介导的疾病，如糖尿病。还提供了治疗或预防以葡萄糖激酶活性不足为特征或可通过激活葡萄糖激酶治疗的疾病和失调的方法。